For patients, medicines are the difference between life and death, a good day or a painful one. But the onus of delivering on this promise rests on the product pack.
Ironically, the part of the product most important to ensuring its worth is worthless and even considered an ecological burden after its job is done.
The impact of packaging is felt only when it does not do its job and therefore pharmaceutical companies have traditionally invested quite a bit on product packs, also using them as part of their branding strategy.
But with increasing pressure on pharma companies to reduce their carbon footprint, the fundamentals of pharma product packaging are being re-written.
As per a Future Market Insights report, the global sustainable pharma packaging market size is projected to grow from US$ 96 billion in 2024 to US$ 410 billion by 2034, reflecting a 15.6 per cent CAGR.
The report titled, Sustainable Pharmaceutical Packaging Market Outlook (2024 to 2034), lists trends like switching to renewably sourced compostable materials which spontaneously decompose into organic molecules, decreasing waste and having a minimal negative environmental impact.
The rise of robotics and automation integration in packaging processes and developing modular and reconfigurable packaging solutions are also mentioned in the report as are trends like investigations into edible pharmaceutical packaging materials derived from natural substances as a sustainable alternative.
Shivshankar S.R, CEO, ACG Packaging Materials says that pharma companies can look at a number of measures to reduce their carbon footprint, which could include using single polymer plastic when it comes to packaging materials and reducing overall packaging size.
This story is from the December 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 2024 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
CILICANT is changing the way we think about active packaging
Team CILICANT shared insights into their journey of innovation, customer-centric solutions, and their ambitious plans for global expansion. In this engaging dialogue, the team also shed light on their unique value proposition, recent achievements, and strategies for adapting to a rapidly evolving pharma landscape, in an exclusive conversation with Express Pharma
KPMG 2024 Life Sciences CEO Outlook
This recent KPMG report explores the perspectives and priorities of life sciences CEOs amid economic and geopolitical uncertainty, focusing on growth strategies, digital transformation, ESG goals, and workforce challenges. Excerpts from the report
Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends
Industry experts highlight the evolving dynamics, regulatory needs, and personalised solutions driving the nutra market ahead of 2025
We aim to strengthen our presence in Asian and MENA regions, with particular emphasis on India
Matthias Poslovski, Chief Sales Officer, Optima Pharma, speaks on the company's evolution and shares insights on emerging trends like personalised medicine, digitalisation, and Al-driven technologies, while outlining his company's strategies for market expansion, particularly in Asia and MENA, with a focus on the Indian pharma sector, in an exclusive interaction with Lakshmipriya Nair
Sustaining excellence: The evolving role of quality in pharma
In the ever-evolving landscape of the pharma industry, the pursuit of quality remains a cornerstone of success. As stringent regulatory frameworks, rising patient expectations, and the increasing pace of innovation, transforms the pharma industry, the definition of quality is also evolving. From ensuring compliance with global standards to embracing cutting-edge technologies like Al-driven quality control, the industry is navigating a paradigm shift in how it approaches product integrity, safety, and efficacy. In this New Year issue, pharma experts explore how crucial it is to foster a culture of quality across organisations and deliver better healthcare outcomes
Revolutionising pharma the adaptive way
Adaptive manufacturing offers better performance, efficient management of diverse products, a reduced machine footprint, faster batch changes, and enhanced operational sustainability
Trends 2025: Redefining the pharma supply chain
Saurabh Gupta, Global Head of Supply Chain, Lupin highlights trends such as Al integration, digitalisation and sustainability that are shaping a future-ready supply chain
Growth mantras for 2025: Innovation, Partnerships, Sustainability
Innovation, synergy, and sustainability are shaping the trajectory of India's pharma sector, unlocking new frontiers of growth, inform industry stakeholders
Will Epygen's biosimilars bets pay off?
Debayan Ghosh, founder, Epygen Group, has ambitious plans to snag a slice of the booming $70 billion global biosimilar pie. In a conversation with Viveka Roychowdhury, he analyses the journey so far, spanning pandemic preparedness projects like protein-based vaccines, building up pipeline revenue streams in diabetes, oncology, immunology and cardiovascular biosimilars, and his strategies to scale up and expand to other therapeutics like anti-obesity drugs
Innovation, partnerships and best practices: Priorities for biopharma in 2025
Industry experts highlight the progress made by the Indian biopharma sector, and suggest pathways to promote growth